^
    almost3years
    Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib (ELCC 2022)
    P1, P2 | "ctDNA next-generation sequencing represents a promising technology but its optimal integration into testing NTRK gene fusions or resistance mutations still remains to be determined. Known resistance mutations in NTRK may cause progression, but further studies are warranted."
    Clinical • Circulating tumor DNA
    |
    FGFR2 (Fibroblast growth factor receptor 2) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ARID1A (AT-rich interaction domain 1A) • SMAD4 (SMAD family member 4) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ARID1A mutation • FGFR2 mutation • FGFR2 fusion • ARID1A K1238fs + FGFR2 R210Q • NTRK1 F589L + NTRK1 G595R • NTRK1 G595R • SMAD4 R361C • NTRK fusion
    |
    Guardant360® CDx • GuardantOMNI
    |
    Vitrakvi (larotrectinib)